|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Supplemental Table 5.Baseline patient demographics, characteristics, and EGFR mutation data according to EGFRmutation status combination subgroup. | | | | |
| **Characteristic** | **Category** | **T790M Only**  **(n = 372)** | **T790M + Common Mutations\***  **(n = 2589)** | **T790M + Uncommon† / Compound‡ Mutations**  **(n = 53)** |
| Country, n (%) | China | 89 (24) | 1244 (48) | 17 (32) |
|  | Italy | 102 (27) | 402 (16) | 6 (11) |
|  | South Korea | 20 (5) | 439 (17) | 7 (13) |
|  | Taiwan | 55 (15) | 131 (5) | 2 (4) |
|  | Spain | 25 (7) | 102 (4) | 4 (8) |
|  | Canada | 15 (4) | 83 (3) | 1 (2) |
|  | Brazil | 6 (2) | 76 (3) | 6 (11) |
|  | Austria | 32 (9) | 14 (1) | 0 |
|  | Australia | 0 | 28 (1) | 3 (6) |
|  | Belgium | 4 (1) | 24 (1) | 3 (6) |
|  | Argentina | 22 (6) | 7 (< 1) | 1 (2) |
|  | United Kingdom | 1 (< 1) | 16 (1) | 1 (2) |
|  | Ireland | 0 | 10 (< 1) | 0 |
|  | Sweden | 1 (< 1) | 4 (< 1) | 2 (4) |
|  | Denmark | 0 | 6 (< 1) | 0 |
|  | Saudi Arabia | 0 | 3 (< 1) | 0 |
| Age | Median (range), years | 63 (35–92) | 62 (27–92) | 59 (30–80) |
|  | < 65 years, n (%) | 203 (55) | 1558 (60) | 37 (70) |
|  | ≥ 65 years, n (%) | 169 (45) | 1031 (40) | 16 (30) |
| Sex, n (%) | Female | 260 (70) | 1637 (63) | 30 (57) |
|  | Male | 112 (30) | 952 (37) | 23 (43) |
| Ethnicity, n (%) | Asian | 178 (48) | 1878 (73) | 29 (55) |
|  | White | 193 (52) | 681 (26) | 23 (43) |
|  | Black | 0 | 21 (1) | 0 |
|  | Other | 1 (< 1) | 9 (< 1) | 1 (2) |
| WHO PS, n (%) | 0 | 119 (32) | 659 (25) | 13 (25) |
|  | 1 | 218 (59) | 1654 (64) | 35 (66) |
|  | 2 | 35 (9) | 275 (11) | 5 (9) |
|  | Missing | 0 | 1 (< 1) | 0 |
| Disease stage at diagnosis, n (%) | Stage 0 | 1 (< 1) | 4 (< 1) | 0 |
|  | Stage IA/IB | 16 (4) | 132 (5) | 8 (15) |
|  | Stage IIA/IIB | 14 (4) | 89 (3) | 1 (2) |
|  | Stage IIIA | 23 (6) | 153 (6) | 2 (4) |
|  | Stage IIIB/IV | 318 (85) | 2203 (85) | 42 (79) |
|  | Missing | 0 | 8 (< 1) | 0 |
| Time between diagnosis and enrollment, months | Median (range) | 23 (1–141) | 24 (1–245) | 23 (3–151) |
| Previous EGFR-TKI treatment\*\*, n (%) | Gefitinib | 194 (52) | 1499 (58) | 29 (55) |
|  | Erlotinib | 122 (33) | 756 (29) | 26 (49) |
|  | Icotinib | 20 (5) | 349 (13) | 2 (4) |
|  | Afatinib | 80 (22) | 211 (8) | 4 (8) |
|  | Other | 4 (1) | 59 (2) | 1 (2) |
| Previous anticancer treatment, n (%) | Chemotherapy | 176 (47) | 243 (48) | 24 (45) |
|  | Radiotherapy | 138 (37) | 966 (37) | 25 (47) |
|  | Surgery | 90 (24) | 628 (24) | 12 (23) |
|  | Antiangiogenic therapy | 11 (3) | 114 (4) | 3 (6) |
|  | Immunotherapy | 13 (3) | 45 (2) | 5 (9) |
|  | Other | 8 (2) | 73 (3) | 2 (4) |
| Time between last anticancer therapy and enrollment, months | Median (range) | 0.7 (0–23) | 0.5 (0–43) | 0.6 (0–15) |
| EGFR testing sample type | Blood | 269 (72) | 59 (37) | 19 (36) |
|  | Tissue | 91 (24) | 1492 (58) | 34 (64) |
|  | FNA/cytology | 5 (1) | 80 (3) | 0 |
|  | Body fluids/other | 6 (2) | 56 (2) | 0 |
|  | Bone marrow | 0 | 1 (< 1) | 0 |
|  | Missing | 1 (< 1) | 1 (< 1) | 0 |
| EGFR mutation positive status, n/N†† (%) | T790M | 372/372 (100) | 2589/2589 (100) | 53/53 (100) |
|  | Exon 19 deletion | 0/140 (0) | 1689/2556 (66) | 21/51 (41) |
|  | L858R | 0/139 (0) | 900/2466 (36) | 17/50 (34) |
|  | G719X | 0/122 (0) | 0/2346 (0) | 30/48 (63) |
|  | S768I | 0/125 (0) | 0/2352 (0) | 17/49 (35) |
|  | Exon 20 insertion | 0/129 (0) | 0/2389 (0) | 4/47 (9) |
| \* Common mutations are T790M + Exon 19 deletion only and T790M + L858R only.  † Uncommon mutations are T790M + G719X only, T790M + S768I only, and T790M + Exon 20 insertion only.  ‡ Compound mutations are T790M + two common mutations or T790M + two or more mutations including at least one uncommon mutation.  \*\* Patients may have received more than one prior EGFR-TKI.  †† Number of patients with positive status/the number of patients tested for the mutation.  EGFR: epidermal growth factor receptor; FNA: fine needle aspiration; TKI: tyrosine kinase inhibitor; WHO PS: World Health Organization performance status. | | | | |